Foghorn Therapeutics (FHTX) Net Equity Issued and Repurchased (2020 - 2026)
Foghorn Therapeutics (FHTX) posted quarterly Net Equity Issued and Repurchased of $50.0 million for Q1 2026, up 19.26% quarter-over-quarter from $41.9 million in Q3 2020.
Powered by 
Analysis
Foghorn Therapeutics (FHTX) Net Equity Issued and Repurchased (2020 - 2026) Analysis & Trends
Foghorn Therapeutics' Net Equity Issued and Repurchased history runs 2 years deep, the most recent figure standing at $50.0 million for Q1 2026.
- In Q1 2026, Net Equity Issued and Repurchased changed N/A year-over-year to $50.0 million; the TTM figure through Mar 2026 stood at $50.0 million (changed N/A YoY), while the FY2024 annual figure was $103.4 million, changed N/A from the prior year.
- Net Equity Issued and Repurchased for Q1 2026 stood at $50.0 million, up from $41.9 million in the prior quarter.
- The five-year high for Net Equity Issued and Repurchased was $50.0 million in Q1 2026, with the low at $50.0 million in Q1 2026.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Equity Issued and Repurchased (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 49.20 Mn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | - |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | 141.90 Mn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | - |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | - |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | - |
| 10 | Foghorn Therapeutics | 347.75 Mn | 279.67 Mn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Mar 31, 2026 | 50.00 Mn |
| Dec 31, 2025 | 540,000.00 |
| Sep 30, 2020 | 41.93 Mn |